Barclays Turns Bearish on Janux: Lead Program JANX007 Loses Confidence
Barclays cut Janux Therapeutics to Underweight, citing doubts on JANX007 and limited near-term upside despite long-term potential.
/ 3 items
#JANX↓
Janux Therapeutics Partners with Bristol Myers Squibb in Major Cancer Drug Deal
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
Janux's Prostate Cancer Drug Shows Declining Response Rates in Early Trial Data
Janux Therapeutics' (JANX) JANX007 immunotherapy disappoints with only 30% response rate in heavily pre-treated prostate cancer patients, raising concerns about efficacy.